Protalix Biotherapeutics, Inc. (PLX)
1.985
0.00 (0.00%)
USD |
NYAM |
Jun 10, 16:00
1.98
0.00 (0.00%)
After-Hours: 20:00
Protalix Biotherapeutics Price to Book Value : 2.379 for June 10, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 2.373 |
| June 08, 2026 | 2.349 |
| June 05, 2026 | 2.385 |
| June 04, 2026 | 2.409 |
| June 03, 2026 | 2.349 |
| June 02, 2026 | 2.385 |
| June 01, 2026 | 2.469 |
| May 29, 2026 | 2.529 |
| May 28, 2026 | 2.517 |
| May 27, 2026 | 2.541 |
| May 26, 2026 | 2.565 |
| May 22, 2026 | 2.517 |
| May 21, 2026 | 2.433 |
| May 20, 2026 | 2.409 |
| May 19, 2026 | 2.277 |
| May 18, 2026 | 2.289 |
| May 15, 2026 | 2.373 |
| May 14, 2026 | 2.397 |
| May 13, 2026 | 2.313 |
| May 12, 2026 | 2.289 |
| May 11, 2026 | 2.325 |
| May 08, 2026 | 2.325 |
| May 07, 2026 | 2.373 |
| May 06, 2026 | 2.421 |
| May 05, 2026 | 2.349 |
| Date | Value |
|---|---|
| May 04, 2026 | 2.553 |
| May 01, 2026 | 2.541 |
| April 30, 2026 | 2.577 |
| April 29, 2026 | 2.541 |
| April 28, 2026 | 2.541 |
| April 27, 2026 | 2.589 |
| April 24, 2026 | 2.613 |
| April 23, 2026 | 2.565 |
| April 22, 2026 | 2.637 |
| April 21, 2026 | 2.661 |
| April 20, 2026 | 2.720 |
| April 17, 2026 | 2.780 |
| April 16, 2026 | 2.756 |
| April 15, 2026 | 2.852 |
| April 14, 2026 | 2.828 |
| April 13, 2026 | 2.744 |
| April 10, 2026 | 2.756 |
| April 09, 2026 | 2.732 |
| April 08, 2026 | 2.696 |
| April 07, 2026 | 2.625 |
| April 06, 2026 | 2.649 |
| April 02, 2026 | 2.577 |
| April 01, 2026 | 2.625 |
| March 31, 2026 | 2.601 |
| March 30, 2026 | 3.492 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Agenus, Inc. | -- |
| Altimmune, Inc. | 1.201 |
| Humacyte, Inc. | 25.78 |
| Amgen, Inc. | 19.83 |
| BioCryst Pharmaceuticals, Inc. | -- |
Price to Book Value Related Metrics
| PE Ratio | 10.83 |
| PS Ratio | 2.115 |
| PEG Ratio | 0.0322 |
| Price to Free Cash Flow | 12.43 |
| Price | 1.985 |
| Earnings Yield | 9.23% |
| Market Cap | 159.93M |
| PEGY Ratio | 0.0322 |
| Operating PE Ratio | 8.163 |
| Normalized PE Ratio | 10.83 |